- Home
- BDTX vs QNCX Comparison
BDTX vs QNCX Comparison
Compare BDTX & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BDTX | QNCX |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.1M | 167.0M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BDTX | QNCX |
|---|---|---|
| Price | $2.48 | $0.17 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 3 |
| Target Price | ★ $10.40 | $10.00 |
| AVG Volume (30 Days) | 903.9K | ★ 3.7M |
| Earning Date | 03-05-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $70,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.20 | $0.16 |
| 52 Week High | $4.94 | $4.55 |
Technical Indicators
Market Signals| Indicator | BDTX | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 40.70 | 20.98 |
| Support Level | $2.49 | $2.92 |
| Resistance Level | $2.70 | $3.41 |
| Average True Range (ATR) | 0.15 | 0.51 |
| MACD | 0.01 | -0.29 |
| Stochastic Oscillator | 24.47 | 0.27 |
Price Performance
Historical ComparisonAbout BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.